M
Mark E. Cooper
Researcher at University of Queensland
Publications - 1514
Citations - 141899
Mark E. Cooper is an academic researcher from University of Queensland. The author has contributed to research in topics: Diabetes mellitus & Diabetic nephropathy. The author has an hindex of 158, co-authored 1463 publications receiving 124887 citations. Previous affiliations of Mark E. Cooper include University of Cambridge & University of Adelaide.
Papers
More filters
Journal Article
Macrophage and myofibroblast proliferation in remnant kidney: Role of angiotensin II
Leonard L. Wu,N Yang,Chris J. Roe,Mark E. Cooper,Richard E. Gilbert,Robert C. Atkins,Hui Y. Lan +6 more
TL;DR: In conclusion, inhibition of local macrophage and myofibroblast proliferation may be an important mechanism by which Ang II blockade attenuated renal injury following renal ablation.
Journal ArticleDOI
AT2R Agonist, Compound 21, Is Reno-Protective Against Type 1 Diabetic Nephropathy
Christine Koulis,Bryna S.M. Chow,Maria McKelvey,Ulrike Muscha Steckelings,Thomas Unger,Vicki Thallas-Bonke,Merlin C. Thomas,Mark E. Cooper,Karin Jandeleit-Dahm,Terri J. Allen +9 more
TL;DR: It is demonstrated that monotherapy of Compound 21 is protective against the progression of experimental diabetic nephropathy by inhibiting renal oxidative stress, inflammation, and fibrosis.
Journal ArticleDOI
Direct quantification of analyte concentration by resonant acoustic profiling
Benjamin Godber,Kevin S.J. Thompson,Marian Rehak,Yildiz Uludag,Sven Kelling,Alexander Sleptsov,Mark John Frogley,Klaus Wiehler,Christopher Durham Whalen,Mark E. Cooper +9 more
TL;DR: Resonant Acoustic Profiling detects analytes in a relatively simple receptor-binding assay in <10 min and may lead to simple, label-free, high-sensitivity methodologies for reagent and assay validation in clinical chemistry and, ultimately, for real-time in vitro diagnostics.
Journal ArticleDOI
Spectrum of proteinuria in type I and type II diabetes
TL;DR: The phase of intermittent proteinuria detected in this study may represent a reversible stage in the development of diabetic nephropathy, but the factors that trigger the transition to progressing proteinuria remain obscure.
Journal ArticleDOI
The Amino-terminal Domains of the Ezrin, Radixin, and Moesin (ERM) Proteins Bind Advanced Glycation End Products, an Interaction That May Play a Role in the Development of Diabetic Complications
TL;DR: The isolation and identification of novel AGE-binding proteins from diabetic rat kidneys represent a novel family of intracellular binding molecules for glycated proteins and provide a potential new target for therapeutic intervention in the prevention or treatment of diabetic complications.